Sickle cell disease-modifying drugs: hydroxyurea and newer options

Separate long-term prevention from crisis treatment

These medicines are taken every day or on a schedule to reduce how often crises happen. They are not analgesics and will not relieve pain during an acute episode. Hydroxyurea is used in people aged two and older to reduce painful crises and the need for transfusions, and families should understand that benefit builds with consistent use.

This distinction matters in exam questions. A child in an acute pain crisis needs the crisis pathway, including assessment, analgesia and hydration as ordered, while continuing the disease-modifying drug is a separate decision for the prescriber. Avoid answers that offer hydroxyurea as the immediate response to acute pain.

Before teaching, find out what the family already understands about the disease and what they expect from the medicine. Many parents equate a daily capsule with a cure. Clarifying that the goal is fewer crises and fewer transfusions, not an immediate change, sets realistic expectations and supports long-term adherence.

Monitor blood counts and report fever with hydroxyurea

Hydroxyurea can severely suppress bone marrow production, lowering white cells, platelets and red cells. That increases the risk of infection and bleeding. Regular laboratory tests guide whether treatment continues, so missed blood tests are a safety issue rather than a scheduling problem. Teach families to keep these appointments.

Fever, chills, sore throat, unusual bruising or bleeding need prompt reporting. In a child with sickle cell disease, fever already carries a high priority because of infection risk, and hydroxyurea adds to it. Hydroxyurea may also increase the risk of some cancers, including skin cancer, so sun protection is part of routine teaching.

Teach hazardous-drug handling at home

Hydroxyurea is handled as a hazardous drug. Caregivers should wear disposable gloves when handling capsules or tablets and wash hands before and after. People who are not taking the medicine, particularly anyone who is pregnant or planning pregnancy, should avoid touching it. Store it out of reach of children and pets.

Ask the pharmacist how the household should prepare doses for a young child so that handling is kept to a minimum. Clean spills as advised and dispose of unused medicine through take-back routes rather than household waste. Confirm understanding by asking the caregiver to describe their routine at home.

Plan contraception and know the newer options

Hydroxyurea can harm a developing baby. People who could become pregnant are advised to use effective contraception during treatment and for months after stopping, and those who could father a child are also advised to use contraception during and after treatment. It may reduce male fertility. These conversations should be age-appropriate and revisited as adolescents mature. Discuss the timing of these conversations with the haematology team, and make sure adolescents can ask questions privately.

Crizanlizumab is an IV monoclonal antibody given by health professionals to reduce pain crises in people aged 16 and older; infusion reactions can occur within 24 hours, with fever, chills, rash or breathing difficulty. L-glutamine is an oral powder mixed with liquid or soft food for people aged five and older; constipation, nausea and abdominal pain are common.

Work a hypothetical home-care question

Imagine a hypothetical eight-year-old taking hydroxyurea whose mother is newly pregnant and asks how to give the medicine safely. Options include continuing to handle capsules with bare hands but washing afterwards, asking another adult to prepare doses with gloves where possible while the mother avoids contact, or stopping the medicine until after the pregnancy.

Arranging gloved handling by someone else, or gloved handling with careful hand hygiene if no one else can help, is the strongest answer. Bare-hand handling ignores the hazard. Stopping the drug removes needed protection for the child without prescriber input. The nurse should involve the pharmacist and haematology team in planning.

Sources and further reading

MedlinePlus: Hydroxyurea. Sickle cell indication, bone marrow suppression, cancer risk and sun protection, contraception for both sexes, glove handling and laboratory monitoring.

MedlinePlus: Crizanlizumab-tmca Injection. Reduction of pain crises from age 16, IV administration by professionals and infusion reactions within 24 hours.

MedlinePlus: L-glutamine. Oral powder for sickle cell from age five, mixing with liquid or soft food and common side effects.